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Neglected tropical diseases (NTDs) are
the most common infections of the
world’s poorest people and the leading
causes of chronic disability and poverty in
low- and middle-income countries [1–3].
NTDs (Table 1) especially affect children
and young women of reproductive age
[4], and consequently deprive them of
their health and economic potential [3].
NTDs also impair agricultural productiv-
ity and are an important reason why the
world’s poorest 1.4 billion people who live
below the poverty line cannot escape
destitution and despair [3]. Despite the
devastating effect of these diseases on
health and development, with evidence
that their global burden is as great as that
of any other serious disease [1–3], finan-
cial support for control and elimination
efforts, as well as research and develop-
ment (R&D), have been inadequate [2,5].
Indeed, in Millennium Development
Goal 6 (to ‘‘combat HIV/AIDS, malaria
and other diseases’’), NTDs were not even
specifically mentioned but merely consid-
ered as part of the ‘‘other diseases’’ [6].
However, policy makers are slowly begin-
ning to appreciate the importance of
NTDs.
The World Health Organization
(WHO) has a new Department of Ne-
glected Tropical Diseases, and WHO-
TDR (Special Programme for Research
and Training in Tropical Diseases) has a
new 10-year strategic plan with support
from UN agencies, member states, and
private philanthropies. At the same time,
funding for integrated NTD preventive
chemotherapy control from the govern-
ments of the US and UK has increased
dramatically and is approaching US$100
million annually, while support remains
strong for product development partner-
ships from the Bill & Melinda Gates
Foundation, Me ´decins Sans Frontie `res
(MSF), and a few European governments.
Recently, the new Director of the US
National Institutes of Health, Francis
Collins, has targeted NTDs as a research
priority, and the UK charity Wellcome
Trust has agreed with the multinational
pharmaceutical company Merck & Co. to
allocate substantial funds for a joint, not-
for-profit research center in India to
develop inexpensive ‘‘antipoverty’’ vac-
cines against neglected diseases [7,8].
Additional efforts to combat NTDs are
also being shared among major multina-
tional pharmaceutical companies (i.e.,
Novartis, GlaxoSmithKline, Pfizer, Sa-
nofi-Aventis, Merck & Co.) and others
who have also committed resources and
made investments in research and devel-
opment for these conditions. Thus,
although at present only about 10% of
the global funds required for preventive
chemotherapy and NTD mass drug ad-
ministration have been committed, and
although R&D for NTDs has not even
reached the so-called 10/90 gap [9,10]
(meaning only 10% of available global
R&D spending is committed for diseases
that disproportionately affect 90% of the
world living in low-income and middle-
income countries), there is cautious opti-
mism that such disparities could diminish
in the coming decade.
With a combination of funds from the
group of eight (G8) nations, emerging
economies (e.g., Brazil, India), multina-
tional companies, and private philanthrop-
ic sources, together with a community of
scientists, physicians, and other healthcare
workers, global public health experts and
policy makers committed to NTDs have
begun to deliberate about how future
resources and investments should be best
allocated, particularly in terms of an
appropriate balance between implementa-
tion and R&D. The leadership of key
international agencies such as WHO,
ministries of health in disease-endemic
countries, and the communities themselves
is key to achieve any ambitious strategy.
With a global dialogue now underway, this
is an appropriate time to present an eight-
point manifesto (‘‘a public declaration of
motives and intentions by a government or
by a person or group regarded as having
some public importance’’ [2,11]) for
NTDs.
1. All NTDs are ‘‘tool ready’’
Tools refer partly to the drugs used to
treat NTDs in low- and middle-income
countries, particularly when these are used
as agents of control and elimination
through mass drug administration [12].
Today, most of the NTDs have tools that
could be implemented now, even if for
some diseases such tools are far from being
perfect or complete (Figure 1). For exam-
ple, each year, hundreds of millions of
poor people receive donated or low-cost
generic drugs, which in some epidemio-
logical environments have led to the
elimination of lymphatic filariasis (LF),
onchocerciasis, and trachoma [13–15], as
well as reduction of morbidity for the three
major soil-transmitted helminth infections
(i.e., ascariasis, trichuriasis, and hookworm
infection), and for schistosomiasis (Table 2)
[1–3,12]. At present, populations at risk
for LF and onchocerciasis are receiving
the highest global drug coverage (.40%),
whereas less than 10% of school-aged
children at risk for soil-transmitted hel-
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receiving treatment [12]. To improve
global coverage rates, in many cases the
control of these large-scale–intervention
NTDs could be achieved by simultaneous
administration of several drugs, sometimes
in a so-called ‘‘rapid impact package’’
costing around US$0.50 per person per
year [1–3,12,16,17]. Similarly, leprosy has
been eliminated in many countries
through multi-drug therapy [18]. The
NTD manifesto mandates that mass drug
administration programs continue to ex-
pand until they reach the entire ‘‘bottom
billion’’ who deserves access to essential
medicines. Simultaneously, support must
be provided for parallel operational re-
search to optimize integration of the
different NTD mass treatment programs
and for other aspects of implementation
science.
Tools for NTDs also refer to field-
based diagnostics and vector-control strat-
egies (in some cases using geographic
information systems and remote sensing),
as well as improvements in water and
sanitation. The nearly-complete eradica-
tion of dracunculiasis is an outstanding
example of how non-drug-based ap-
proaches can achieve sustained control
[19]. There have been successes in the
local control of dengue and other arbo-
viral infections through mosquito control
measures [20], and in trachoma elimina-
tion through a combined strategy of
surgery, antibiotics, face washing, and
environmental control (SAFE strategy)
[1,3,12,21].
At present, we can also achieve substan-
tial sustainable control for the important
vector-borne kinetoplastid NTDs (i.e.,
human African trypanosomiasis [HAT],
Chagas disease, and leishmaniasis). For
example, during the early part of the 20th
century, Jamot and his colleagues imple-
mented mobile teams for Gambian HAT
in West Africa. These health teams, with
the logistical support of the military,
traveled to endemic areas to identify
human cases for treatment with either
tryparasamide or, later, pentamidine, to-
gether with a vertically structured vector-
control strategy (i.e., for tse-tse only)
[2,22]. For stage 1 HAT, this approach
using pentamidine is still valid today, while
for stage 2 HAT (affecting the central
nervous system) a new available treatment
is nifurtimox–eflornithine combination
therapy (NECT), which reduces the time
and cost required for treatment with
eflornithine alone and is safer and more
effective than previous arsenical treatment
options [23]. Similarly, new cases of
Chagas disease have been eliminated in
some South American countries through
detection of the bug vectors and insecticide
spraying for vector control, in addition to
programs of diagnostics and treatment
with benznidazole or nifurtimox, providing
medical care to patients, and screening
blood donors [24,25]. Finally, an elimina-
tion program of visceral leishmaniasis has
been launched on the Indian subcontinent
through passive and active case detection,
early diagnosis and treatment, integrated
vector management (including indoor re-
sidual spraying and insecticide-treated bed
nets) and vector surveillance, as well as
environmental management and social
mobilization [26–29].
The NTD manifesto mandates that such
programs of case detection, treatment, and
integrated vector management should also
continue to receive adequate support.
Health education is yet another important
element for prevention, and, for some
NTDs, it is the only available tool (i.e. the
food-borne trematode infection opisthorchi-
asis [30] and Buruli ulcer [31]). Indeed,
with a few possible exceptions, we now
have control tools in hand for almost all
major NTDs, but their use must be
expanded and, where appropriate, im-
proved strategies for their use must contin-
ue to be developed [32], and supported
through a robust program of operational
research and implementation science.
2. All NTDs are ‘‘tool deficient’’
Although tools exist to control, or in
some cases even eliminate, NTDs, for
Table 1. Neglected tropical diseases.
Category Infections
Helminth Infections Ascariasis
Trichuriasis
Hookworm
Strongyloidiasis
Toxocariasis and larva migrans
Lymphatic filariasis
Onchocerciasis
Loiasis
Dracunculiasis
Schistosomiasis
Food-borne trematodiases
Taeniasis-cysticercosis
Echinococcosis
Protozoan Infections Leishmaniasis
Chagas disease
Human African trypanosomiasis
Amebiasis
Giardiasis
Balantidiasis
Toxoplasmosis
Trichomoniasis
Bacterial Infections Bartonellosis
Bovine tuberculosis
Buruli ulcer
Cholera
Enteric pathogens (Shigella, Salmonella, E. coli)
Leprosy
Leptospirosis
Relapsing fever
Trachoma
Treponematoses: Bejel, pinta, syphilis, yaws
Viral Infections Dengue fever
Japanese encephalitis
Jungle yellow fever
Other arboviral infections
Rabies
Rift Valley fever
Viral hemorrhagic fevers
Fungal Infections Mycetoma
Paracoccidiomycosis
Ectoparasitic Infections Scabies
Myiasis
Tungiasis
Modified from http://www.plosntds.org.
doi:10.1371/journal.pntd.0000718.t001
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implementation strategies available are
suboptimal, incomplete, or inadequate to
sustain elimination efforts. Consequently,
substantial investments in R&D are ur-
gently needed to develop new-generation
control tools and strategies for their
improved use and implementation.
The currently available drugs for HAT
are highly toxic or need long treatment
regimens and careful patient monitoring,
which are often difficult in resource-poor
settings or fragile health systems located in
conflict or post-conflict endemic areas
[22,23,33]. NECT is an efficacious and
easier to administer alternative compared
to arsenicals or eflornithine alone [23], but
it is only a temporary suboptimal solution
and better tools are still needed to achieve
HAT elimination. The completed genome
for African trypanosomes and other ki-
netoplastids offers great potential for the
development of new drugs [34]. However,
there is still a big gap between genomics
data and target identification and valida-
tion, and subsequent compound screening.
Several years will be needed to develop
screening hits that become drug candi-
dates through the lead optimization pro-
cess. To respond to the urgent needs of
new, better, and inexpensive treatments
for HAT, several product development
partnerships and WHO-TDR have initi-
ated a systematic search for drug targets
and drugs candidates from existing com-
pounds made by various pharmaceutical
organizations and research institutes [35].
One of the compounds is fexinidazole
[36], which has been now been taken all
the way from discovery and into clinical
development. However, because of the
high attrition rate in drug development,
continued efforts in building the HAT
drug pipeline need to be maintained until
new oral drugs are available.
Similarly for Chagas disease, the two
existing drugs, benznidazole and nifurti-
mox, have several limitations in terms of
safety, questionable efficacy in the pre-
vention of long-term complications asso-
ciated with cardiomyopathy and mega-
colon/megaesophagus, and difficult
delivery in fragile healthcare systems in
the poorest regions of Latin America
[37,38]. In addition, most patients iden-
tified through systematic surveillance are
children, and pediatric formulations do
not exist, although a nascent program to
develop a pediatric formulation of benz-
nidazole is underway. Based on genomics
and proteomics analyses, some new and
promising approaches exist for the devel-
opment of drugs for Chagas disease,
including new agents that target ergos-
terol and trypanothione biosynthesis,
farnesyl-pyrophosphate synthase, purine
salvage pathways, and a unique cysteine
protease known as cruzipain [37,38]. As
with HAT, a systematic search for drug
candidates from the pipelines of pharma-
ceutical companies has been conducted
and several antifungal azoles have been
identified as possible clinical candidates
for the treatment of Chagas disease.
However, because of the lack of clearly
defined efficacy endpoints and no pre-
dictive animal model, drug development
for Chagas disease is a very challenging
task.
For visceral leishmaniasis, the existing
tools still largely depend on antimonials,
which have not yet been optimized to
reduce toxicity and prevent emerging drug
resistance [28,29],. Furthermore, only
three new effective treatments have been
licensed over the past decade, and even
these remain largely inaccessible to most
control programs of leishmaniasis in
resource-poor settings (Table 2) [39].
Although several combination treatments
are under development to prevent the
emergence of drug resistance and to
reduce treatment duration, these are not
going to be enough for disease elimination.
Therefore, the NTD manifesto mandates
urgent action to provide adequate support
for the development of such anti-kineto-
plastid drugs. Vaccines for all three
kinetoplastid infections are also in early-
stage development, and a recombinant
leishmaniasis vaccine is in clinical testing
[7,8,40,41]. Similarly, vaccines for other
nonhelminthic NTDs such as amebiasis
and the neglected mycobacterial infections
Buruli ulcer and leprosy are in early
development [7,8,42–44], and at least
two live attenuated tetravalent vaccine
candidates for dengue fever are in phase
2 clinical trials, with numerous other
vaccine candidates also under develop-
ment [7,8,45,46].
Figure 1. What is needed to combat NTDs?
doi:10.1371/journal.pntd.0000718.g001
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Disease Control Strategy Challenges Research Needs Major Recent Advances
Chagas disease N Interruption of
transmission through vector
control and improved blood
transfusion
N Control of non-domicile vectors; s
N Sustained vector control
N Millions infected at risk of disease
N Strategies for control of
non-domicile vectors
N Better drugs and diagnostics
N Pediatric benznidazole could be
available soon
N New compounds in
development
Dengue N Active surveillance and
case management
N Selective vector control
N Poor mosquito control
N Increase in man-made risk factors
N Case management in epidemics
N Better methods for
mosquito control
N Better tools: vaccines,
drugs, case management
N Vaccines in development
Human African
trypanosomiasis
(HAT)
N Active surveillance, case
finding and treatment
N Selective vector control
N Poor surveillance
N Poor diagnostics
N Toxic drugs
N Better tools: drugs and
diagnostics
N Development of simplified
HAT treatment: NECT
N Fexinidazole in
development stage
Leishmaniasis N Case finding and
treatment
N Selective vector/animal
reservoir control, elimination
in the Indian subcontinent
N Long, difficult, expensive treatment
N Practical limitations of diagnostics
N Low priority
(cutaneous leishmaniasis)
N Poor health systems
N Better tools: drugs and
diagnostics
N Better case-finding and
treatment strategies
N Anti-leishmania vaccine
N Paromomycin, miltefosine,
liposomal amphotericin B
N Combination therapies
N Vaccine in development
Leprosy N Case-finding and
multi-drug treatment
N Incomplete multi-drug
treatment coverage
N Integrating/sustaining control
N Impact on transmission
not known
N Integration of
leprosy control
N Improved diagnosis of
infection
N Simplified multi-drug
treatment regimen
N Possible BCG vaccination
strategies
N Elimination achieved
in many countries
N Re-evaluation of
elimination targets
Lymphatic
filariasis
N Interruption of
transmission through
periodic mass treatment
N Disability alleviation
by local hygiene
N Elimination target by 2020
N Limited effect of current drugs
N Co-endemicity
(loa loa, onchocerciasis)
N Shorten duration of control
measures
N Drugs that kill/sterilize adult
worms (macrofilaricide)
N New detection methods
N Elimination of transmission
in several countries
N Ivermectin donation (Merck)
and albendazole (GSK)
N Some antibiotics (tetracycline,
rifampicin) found effective
Onchocerciasis N Periodic mass treatment
to eliminate the disease as
a public health problem
N Need to sustain high coverage
N Eradication not possible with
current tools
N Limited effect of current drug
N Over-reliance on one single drug
N Co-endemicity (loa loa)
N Drugs that kill/sterilize
adult worms (macrofilaricide)
N Shorten duration of control
measures
N New detection methods
N Resistance markers
N Ivermectin donation (Merck)
N Some antibiotics (tetracycline,
rifampicin) found effective
N Moxidectin in
development stage
N Control in ten west
African countries
N No new cases of blindness due
to onchocerciasis in the Americas
in the past decade
Soil-transmitted
Helminth Infections
N Morbidity control
through periodic mass
treatment
N WHO target to treat .75%
school-age children at risk
N Inclusion of pre-school
children (,5y )
N Low cure rates with single dose
N Over-reliance on one single drug
N Operational research to
integrate with other NTD
control efforts and to
improve coverage
N Better drugs or
combination of drugs
N Better control measures
N Resistance markers
N Antihelminthic vaccines to
prevent re-infection and
forestall drug resistance
N New antihelminthic drugs
N Human hookworm vaccine
in development
Schistosomiasis N Morbidity control through
periodic treatment in high-risk
populations
N WHO target to treat .75%
school-age children at risk
N Limited availability of praziquantel
N Over-reliance on one single drug
N Operational research to
integrate with other NTD control
efforts and to improve coverage
N Better drugs or combinations
N Resistance markers
N Antihelminthic vaccines to
prevent re-infection and
forestall drug resistance
N Antimalarial drugs found
effective
N New drug candidates
N Decreased prevalence in some
countries
N Partial donation of
praziquantel (Merck KGaA)
N At least two vaccines in
development
Trachoma N SAFE (surgery, antibiotics,
face washing, environmental
control) strategy
N Global elimination of trachoma
by the year 2020
N Over-reliance on one single drug
N Operational research to
integrate with other NTD control
efforts and to improve coverage
N Elimination in selected
countries
doi:10.1371/journal.pntd.0000718.t002
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tions (the world’s most common NTDs),
albendazole is still the only agent available
that can treat all three major infections
(i.e., ascariasis, trichuriasis, and hookworm
infection) when used as a single dose in
mass drug administration campaigns. Al-
though mebendazole can still be used for
ascariasis, a recent meta-analysis has
shown that single-dose mebendazole has
high failure rates against hookworm [47].
This finding means that we must rely on a
single drug to treat more than one billion
infected people every year, despite the fact
that this class of benzimidazole anthelmin-
thic is highly susceptible to drug resistance
when widely used to deworm livestock
[48]. Therefore, development of new
anthelminthics, such as the amino-aceto-
nitrile derivatives that are highly effective
as veterinary agents [48], or tribendimi-
dine, a nicotinic acetylcholine receptor
agonist discovered in China [49], is
urgently needed. Alternatively, mebenda-
zole or albendazole could be combined
with other existing anthelminthic drugs
(i.e., pyrantel or levamisole) to reduce
development of drug resistance, and a
new Bacillus thuringiensis crystal protein is
showing promise in preclinical testing
[50]. A human hookworm vaccine is
under product and clinical development
and would be used in a program of
vaccine-linked chemotherapy to prevent
hookworm reinfection after treatment
[7,8,51]. Similarly, for schistosomiasis
praziquantel is the only available agent
to treat more than 200 million people, and
while drug resistance has not been clearly
shown, development of new drugs through
automated screening [52,53], or by min-
ing the genome [54] is urgently needed.
Anti-schistosome vaccines together with
chemotherapy are an important new
option [7,8,55], and there is a need to
think about how to integrate such new
tools into changing demographic, health,
and social systems [56]. For both oncho-
cerciasis and LF, if a macrofilaricide was
available (i.e., a drug for mass distribution
that destroys the adult worm), as opposed
to the existing microfilaricidal drugs iver-
mectin and diethylcarbamazine citrate,
fewer rounds of annual distribution would
be necessary and elimination efforts would
be made much more efficient [57].
Antibiotics that destroy the parasite’s
bacterial symbionts are also being ex-
plored for this purpose [58].
For most of the major NTDs, the
current approaches to diagnosis and case
detection were developed in the early- or
mid-twentieth century. There is an urgent
need to develop new diagnostics and
rapidly introduce them into ongoing and
future control programs [59,60].
As the US and UK Governments
increase funding for integrated NTD
control, there is an urgent need to also
increase significantly R&D efforts devel-
oped by product development partner-
ships and other organizations. Indeed, the
poorest people living in low- and middle-
income countries have the right to access
not only essential medicines but also
innovation. Unfortunately, global initia-
tives, especially from the G8 nations, have
largely lacked efforts to support R&D. The
George Institute has recently analyzed
how much money is invested every year
on R&D for neglected diseases [5]. About
three-quarters of total neglected disease
R&D annual spending is for HIV/AIDS,
malaria, and tuberculosis, leaving only
about US$600 million worldwide for all
NTDs per year, with only US$139 million
for all kinetoplastid infections, US$132
million for diarrheal diseases, US$127
million for dengue, US$67 million for all
human helminth infections, and less than
US$10 million for each neglected myco-
bacterial infection, trachoma, and Buruli
ulcer [5]. Because of the huge disease
burden from these infections, such modest
R&D support reflects what may be a 1/99
gap relative to other chronic diseases in
developed nations. We also need to ensure
funds are made available for clinical
research (which is expensive) into new
drugs and vaccines. The development of
truly modern antimicrobial/antiparasitic
agents and vaccines will take many years
and is likely to remain a high-risk
endeavor with respect to the level of
investment in R&D and the high attrition
rate of drug discovery. In order to facilitate
this research, and due to the pressing
needs in NTDs, governments and regula-
tors need to ensure that incentives and
enabling regulatory systems are made
available to product developers [61].
3. All NTDs are ‘‘most
neglected’’
Because of the great disease burden of
NTDs and the absence of adequate
funding to support their control or elim-
ination, each of the major NTDs listed in
Table 1 should be considered as severely
neglected. In contrast, diseases such as
malaria and tuberculosis have been also
neglected but they have received signifi-
cantly more attention during the past ten
years from the international community,
with the creation of the US President’s
Emergency Plan for AIDS Relief, the US
President’s Malaria Initiative, the Global
Fund to Fight AIDS, Tuberculosis, and
Malaria, and considerable R&D invest-
ments from the Bill & Melinda Gates
Foundation, NIH, Wellcome Trust, and at
least five dedicated product development
partnerships for drugs and vaccines to
combat these conditions [5]. Funding for
NTD control and R&D should be brought
closer to the level of current support for
HIV/AIDS, malaria, and tuberculosis.
4. There is a profound human
rights dimension to NTDs
Although poverty is surely one of the
main risk factors for neglected diseases,
increasing evidence indicates an associa-
tion between their prevalence and conflict
and violation of human rights [62]. As
noted above, NTDs affect the poorest of
the poor, who have no economic and
political power and are very often neglect-
ed by their governments. Many NTDs are
disfiguring, causing severe social conse-
quences. Most affected populations live in
remote areas with limited or no access to
treatment or prevention. Indigenous or
aboriginal people are also disproportion-
ately affected by NTDs [63], while in the
Americas NTDs were introduced through
the Atlantic slave trade and to this day
they disproportionately affect non-white
people [64,65]. NTDs are found wherever
extreme poverty occurs—not only in
developing countries but in poor areas in
developed countries including the USA
and Europe [64,66]. Mahatma Gandhi
(who himself suffered from hookworm
infection [67]) once said that a ‘‘civiliza-
tion is judged by the treatment of its
minorities’’ [68]. This observation is
particularly relevant for people living with
neglected diseases, which generally can be
either treated or prevented at low cost.
5. NTDs destabilize societies
and contribute to conflict
Many poor societies have either been
recently engaged in a civil or international
conflict or are currently at war [69]. The
potentially destablilizing effects of NTDs,
especially on agricultural productivity and
food security, may partly explain why
considerable geographic overlap has been
observed between NTDs and recent
conflict, especially for HAT, leishmaniasis,
and onchocerciasis in sub-Saharan Africa
[67,70]. These conditions are likely to
substantially contribute to conflict in low-
income countries [62,67,70]. At a com-
munity level, the disease burden may
destabilize a settlement to a point that
entire villages are abandoned. Conflict
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with no functioning national disease pro-
gram. In these situations, medical human-
itarian assistance and innovative health
strategies are greatly needed to combat
NTDs [71].
6. Involvement by the WHO and
other international health
agencies is crucial for current
and future NTD control
The community working on NTDs
greatly appreciates the active involvement
of the WHO, through their new Depart-
ment of Neglected Tropical Diseases,
WHO-TDR, and the regional offices.
The technical advisory role and convening
power of the WHO and their regional
offices, and their active contributions to
global control and elimination efforts,
indicate success and commitment. Accord-
ingly, WHO is absolutely essential for the
future global control and elimination
efforts supported by governments and
private partners (NGOs, pharmaceutical
companies, and philanthropic organiza-
tions). At the same time, it needs to be
recognized that WHO is not alone in this
success. UNICEF (United Nations Inter-
national Children’s Emergency Fund),
UNDP (United Nations Development
Program), FAO (Food and Agricultural
Organization), the World Bank and sev-
eral regional banks, as well as the NTD
control public–private partnerships, have
greatly contributed to global NTD control
and elimination, and their ongoing
efforts should be both applauded and
encouraged.
7. Building health systems
under the leadership of health
ministries in disease-endemic
countries and the communities
is a high priority
Nothing is more important to the
success of global NTD control than the
involvement of communities themselves,
with disease-endemic countries’ health
ministries providing leadership. Commu-
nity-directed treatments for ivermectin, for
instance, have helped the establishment of
a key health system for onchocerciasis
control [72,73]. This and similar activities
account for much of the high-level cover-
age for onchocerciasis and LF [73], and
are vital for ensuring that in the near
future treatment coverage for soil-trans-
mitted helminth infections, schistosomia-
sis, and other NTDs reaches similar levels.
In many areas of conflict and postconflict
in Africa, community involvement in
NTD control is one of the few actively
functioning health systems. Such activities
have facilitated the delivery of additional
interventions such as insecticide-treated
bed nets, antimalarial drugs, micronutri-
ents, and childhood immunizations [74].
The coordination and leadership by health
ministries is crucial to achieve sustainable
control and elimination efforts for NTDs
in integrating the different vertical strate-
gies into a coordinated, strengthened
public health system. To this end, NTDs
need to be prioritized at the level of health
ministries. This can occur with greater
awareness and improved funding mecha-
nisms for local control programs.
8. Moving forward through a
global strategy combining
access and innovation
Millennium Development Goal 8 (‘‘de-
velop a global partnership for develop-
ment’’) advocates for international part-
nerships to achieve all millennium targets
[6]. Under the leadership of international
organizations (WHO and its regional
offices, UNICEF, FAO), all stakehold-
ers—health ministries in disease-endemic
countries, affected communities, public–
private partnerships, research communi-
ties in both endemic and nonendemic
countries, product development partner-
ships for the development of new tools,
large and small nongovernmental organi-
zations—should establish a well-function-
ing international strategy for NTD con-
trol. Global partnerships for NTDs are
involved in the delivery of existing treat-
ments and in the development of new
ones. With adequate support from the G8
Governments and some emerging econo-
mies [75], notably through the G20, the
international NTD community could sub-
stantially reduce poverty and serve as a
highly efficient vehicle for millennium
targets, and all this potentially at costs far
lower than other international initiatives.
Countries affected by NTDs must also
assume responsibility in addressing the
dire health needs of impoverished popula-
tions and work to deliver new policies that
will develop health innovation capacity
through research networks and technology
transfer schemes.
Although NTDs threaten the lives of
millions in the developing world, their
burden on global health is under-recog-
nized, often sidelined, and under-re-
sourced.
Actions are urgently needed to promote
interactions among scientists working on
NTDs, to facilitate the dissemination of
information about NTDs, to identify
funding opportunities and the most cost-
effective ways to fight NTDs, and to
explore possibilities for international col-
laborations for promoting and implement-
ing R&D projects. By highlighting impor-
tant challenges in the fight against NTDs,
this manifesto calls on the global commu-
nity for urgent, renewed, and innovative
efforts.
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